Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies

Abstract

Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib. Dasatinib is superior to imatinib in terms of clinical response; however, the potential pulmonary toxicities associated with dasatinib, such as pulmonary arterial hypertension and pleural effusion, may limit its clinical use. Appropriate management of dasatinib-related severe events is important for improving the quality of life and prognosis of patients with CML. This review summarizes current knowledge regarding the characteristics, potential mechanisms, and clinical management of adverse reactions occurring after treatment of CML with dasatinib.

Systemic Review of Clot Retraction Modulators

“…It works by inhibiting the BCR-ABL tyrosine kinase, an aberrant fusion protein expressed in CML. Hemophilic adverse effects have been documented in many patients taking Dasatinib, which is thought to be due to platelet dysfunction, as well as pancytopenia [ 39 ]. This study focused on the molecular mechanism involved in platelet dysfunction.…”

Right ventricular dysfunction in cancer patients; Is it real or dilemma? A narrative review

“…Tyrosine Kinase Inhibitors (TKI) such as Imatinib and Dasatinib are a group of anti-cancer drugs which made primarily to treat cancers with Philadelphia chromosome (Ph) with BCR-ABL fusion gene like Chronic Myeloid Leukemia (CML) and also as a human epidermal growth factor receptor antagonist in treatment of Renal Cell Carcinoma (RCC) and breast cancer [39][40][41]. In addition to success of TKIs in treatment of cancer, they may cause several adverse effects such as gastrointestinal illness, thyroid dysfunction, bone marrow suppression, hand-foot and mouth disease, and cardiotoxicity [40].…”

Targeting the Bcr-Abl Oncoprotein in Leukemia: Molecular Docking Analysis and Toxicity Prediction of Potential Therapeutic Candidates

“…Agents such as imatinib, dasatinib, and nilotinib are designed to target the Bcr-Abl fusion protein, a hallmark feature of CML. By effectively inhibiting its activity, these medications 2 suppress the growth and proliferation of leukemic cells [11,12]. The current study is centered on Molecular Docking simulations [13,14] utilizing Autodock Vina in conjunction with the Pyrx program ]16].…”